Avandia(rosiglitazone)
Avaglim, Avandamet, Avandaryl, Avandia, Nyracta, Venvia (rosiglitazone) is a small molecule pharmaceutical. Rosiglitazone was first approved as Avandia on 1999-05-25. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against peroxisome proliferator-activated receptor gamma. In addition, it is known to target transient receptor potential cation channel subfamily M member 3, short transient receptor potential channel 5, and free fatty acid receptor 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rosiglitazone maleate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AVANDIA | Woodward Pharma Services | N-021071 DISCN | 1999-05-25 | 3 products, RLD |
Hide discontinued
Metformin hydrochloride
+
Rosiglitazone maleate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AVANDAMET | SB Pharmco | N-021410 DISCN | 2002-10-10 | 5 products, RLD |
Hide discontinued
Glimepiride
+
Rosiglitazone maleate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AVANDARYL | SB Pharmco | N-021700 DISCN | 2005-11-23 | 5 products, RLD |
Hide discontinued
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD03: Metformin and rosiglitazone
— A10BD04: Glimepiride and rosiglitazone
— A10BG: Thiazolidinediones, blood glucose lowering drugs
— A10BG02: Rosiglitazone
HCPCS
No data
Clinical
Clinical Trials
229 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 6 | 4 | 37 | 33 | 22 | 102 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 5 | 29 | 15 | 9 | 57 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 5 | 9 | 5 | 9 | 12 | 38 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 1 | 4 | 1 | 5 | 2 | 12 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | 2 | 6 | 2 | 1 | 11 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 4 | 1 | 2 | 7 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 2 | — | 2 | 2 | 7 |
| Fatty liver | D005234 | EFO_0003934 | — | — | 2 | — | 2 | 1 | 5 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 2 | — | 1 | 1 | 4 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | 2 | 1 | 1 | 4 |
Show 19 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 5 | 5 | 4 | — | 1 | 15 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 3 | — | 3 | 6 |
| Inflammation | D007249 | MP_0001845 | — | — | 2 | 2 | — | 1 | 3 |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | 1 | 1 | 1 | — | — | 3 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | 2 | 1 | — | — | 3 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 1 | 2 | — | 1 | 3 |
| Hypercholesterolemia | D006937 | — | — | — | — | 1 | — | 1 | 2 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | 1 | 2 | — | — | 2 |
| Endometriosis | D004715 | EFO_0001065 | N80 | — | 2 | 1 | — | — | 2 |
| Coronary disease | D003327 | — | — | — | — | 1 | — | — | 1 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 4 | 3 | — | — | 4 | 10 |
| Lipodystrophy | D008060 | — | E88.1 | 3 | 2 | — | — | 1 | 5 |
| Malaria | D008288 | EFO_0001068 | B54 | 2 | 1 | — | — | 1 | 3 |
| Focal segmental glomerulosclerosis | D005923 | EFO_0004236 | — | 1 | 1 | — | — | — | 2 |
| Papillary thyroid cancer | D000077273 | — | — | 1 | 1 | — | — | — | 2 |
| Follicular adenocarcinoma | D018263 | — | — | 1 | 1 | — | — | — | 2 |
| Hyperinsulinism | D006946 | — | E16.1 | — | 1 | — | — | 1 | 2 |
| Pituitary neoplasms | D010911 | — | — | — | 1 | — | — | 1 | 2 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | 1 | 2 | — | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Show 29 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | 2 | 9 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | 1 | 2 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
| Pneumonia | D011014 | EFO_0003106 | J18 | 1 | — | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 1 | — | — | — | — | 1 |
| Metabolism | D008660 | GO_0008152 | — | 1 | — | — | — | — | 1 |
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | — | — | — | — | 1 |
| Vomiting | D014839 | — | R11.1 | 1 | — | — | — | — | 1 |
Show 3 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 2 | 2 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | — | — | 2 | 2 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | — | — | — | 1 | 1 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | — | — | 1 | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | — | — | 1 | 1 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | — | 1 | 1 |
| Latent autoimmune diabetes in adults | D000071698 | — | — | — | — | — | — | 1 | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
| Carotid artery diseases | D002340 | EFO_0003781 | — | — | — | — | — | 1 | 1 |
| Chronic disease | D002908 | — | — | — | — | — | — | 1 | 1 |
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rosiglitazone |
| INN | rosiglitazone |
| Description | Rosiglitazone is an aminopyridine and a member of thiazolidinediones. It has a role as an insulin-sensitizing drug, a ferroptosis inhibitor and an EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor. It is a conjugate acid of a rosiglitazone(1-). |
| Classification | Small molecule |
| Drug class | peroxisome proliferator activiating receptor (PPAR) agonists (thiazolidene derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1 |
Identifiers
| PDB | — |
| CAS-ID | 122320-73-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL121 |
| ChEBI ID | 50122 |
| PubChem CID | 77999 |
| DrugBank | DB00412 |
| UNII ID | 05V02F2KDG (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
RXRA
RXRA
Organism
Homo sapiens
Gene name
RXRA
Gene synonyms
NR2B1
NCBI Gene ID
Protein name
retinoic acid receptor RXR-alpha
Protein synonyms
Nuclear receptor subfamily 2 group B member 1, retinoid X nuclear receptor alpha, Retinoid X receptor alpha
Uniprot ID
Mouse ortholog
Rxra (20181)
retinoic acid receptor RXR-alpha (P28700)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Rosiglitazone
+
Glimepiride
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Rosiglitazone
+
Metformin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Rosiglitazone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 31,126 documents
View more details
Safety
Black-box Warning
Black-box warning for: Avandamet, Avandia
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
112,178 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use